Abstract:BACKGROUND Levodopa is the main treatment for symptoms of Parkinson's disease. Determining whether levodopa also has a disease‐modifying effect could provide guidance as to when in the course of the disease the treatment with this drug should be initiated. METHODS In a multicenter, double‐blind, placebo‐controlled, delayed‐start trial, we randomly assigned patients with early Parkinson's disease to receive levodopa (100 mg three times per day) in combination with carbidopa (25 mg three times per day) for 80 weeks (early‐start group) or placebo for 40 weeks followed by levodopa in combination with carbidopa for 40 weeks (delayed‐start group). The primary outcome was the between‐group difference in the mean change from baseline to week 80 in the total score on the Unified Parkinson's Disease Rating Scale (UPDRS; scores range from 0 to 176, with higher scores signifying more severe disease). Secondary analyses included the progression of symptoms, as measured by the UPDRS score, between weeks 4 and 40 and the noninferiority of early initiation of treatment to delayed initiation between weeks 44 and 80, with a noninferiority margin of 0.055 points per week. RESULTS A total of 445 patients were randomly assigned: 222 to the early‐start group and 223 to the delayed‐start group. The mean (±SD) UPDRS score at baseline was 28.1±11.4 points in the early‐start group and 29.3±12.1 points in the delayed‐start group. The change in UPDRS score from baseline to week 80 was ‐1.0±13.1 points and ‐2.0±13.0 points, respectively (difference, 1.0 point; 95% confidence interval [CI], ‐1.5 to 3.5; P=0.44); this finding of no significant between‐group difference at week 80 implies that levodopa had no disease‐modifying effect. Between weeks 4 and 40, the rate of progression of symptoms, as measured in UPDRS points per week, was 0.04±0.23 in the early‐start group and 0.06±0.34 in the delayed‐start group (difference, ‐0.02; 95% CI, ‐0.07 to 0.03). The corresponding rates between weeks 44 and 80 were 0.10±0.25 and 0.03±0.28 (difference, 0.07; two‐sided 90% CI, 0.03 to 0.10); the difference in the rate of progression between weeks 44 and 80 did not meet the criterion for noninferiority of early receipt of levodopa to delayed receipt. The rates of dyskinesia and levodopa‐related fluctuations in motor response did not differ significantly between the two groups. CONCLUSIONS Among patients with early Parkinson's disease who were evaluated over the course of 80 weeks, treatment with levodopa in combination with carbidopa had no disease‐modifying effect. (Funded by the Netherlands Organization for Health Research and Development and others; LEAP Current Controlled Trials number, ISRCTN30518857.)

Levodopa Impairs the Energy Metabolism of the Basal Ganglia In Vivo

Levodopa Impairs Lysosomal Function in Sensory Neurons In Vitro

Levodopa Imparts a Normalizing Effect on Default-Mode Network Connectivity in Non-Demented Parkinson’s Disease

Levodopa affects functional brain networks in parkinsonian resting tremor

Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson's Disease: A Retrospective Analysis.

Force Overflow and Levodopa-Induced Dyskinesias in Parkinson's Disease.

The Effect of Dopamine Replacement Therapy on Cortical Structure in Parkinson's Disease.

Normalization Effect of Levodopa on Hierarchical Brain Function in Parkinson's Disease.

The Potential Role of Glucose Metabolism, Lipid Metabolism, and Amino Acid Metabolism in the Treatment of Parkinson's Disease.

The Interplay of Mitochondrial Bioenergetics and Dopamine Agonists as an Effective Disease-Modifying Therapy for Parkinson's Disease

Impact of Physical Exercise on Levodopa Therapy Across Parkinson's Disease Stages

Levodopa therapy affects brain functional network dynamics in Parkinson's disease

L-dopa Treatment Increases Oscillatory Power in the Motor Cortex of Parkinson's Disease Patients.

Mechanisms of peripheral levodopa resistance in Parkinson’s disease

Inhibition of neuronal mitochondrial complex I or lysosomal glucocerebrosidase is associated with increased dopamine and serotonin turnover

Comparative Effects of Acute or Chronic Administration of Levodopa to 6-OHDA-lesioned Rats on the Expression and Phosphorylation of N -methyl- d -aspartate Receptor NR1 Subunits in the Striatum

Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review

No effect of a levodopa single dose on motor performance and motor excitability in chronic stroke. A double-blind placebo-controlled cross-over pilot study

Levodopa Reduces the Phase Lag Index of Parkinson's Disease Patients: A Magnetoencephalographic Study.

Rethinking Parkinson's disease: could dopamine reduction therapy have clinical utility?

Randomized Delayed‐Start Trial of Levodopa in Parkinson's Disease